Hunter R W, Alexander N D, Soutter W P
Institute of Obstetrics and Gynaecology, Royal Postgraduate Medical School, Hammersmith Hospital, London, England.
Am J Obstet Gynecol. 1992 Feb;166(2):504-11. doi: 10.1016/0002-9378(92)91658-w.
If maximum cytoreductive surgery benefits the survival of women with advanced ovarian cancer, the median survival time of groups of such women will improve as the proportion of women undergoing maximum cytoreductive surgery is increased.
Fifty-eight suitable studies that encompass 6962 patients with advanced ovarian cancer were identified. Multiple linear regression was used to analyze the effects on median survival time of the following variables: the proportion of each cohort undergoing maximum cytoreductive surgery, the use of platinum-containing chemotherapy, the dose intensity of chemotherapy, the proportion of each cohort with stage IV disease, and the year of publication of the study.
Maximum cytoreductive surgery was associated with only a small improvement in median survival time, but platinum-containing chemotherapy improved median survival time substantially. Increased dose intensity also conferred a useful survival benefit.
Cytoreductive surgery probably has only a small effect on the survival of women with advanced ovarian cancer. The type of chemotherapy used is more important.
如果最大限度肿瘤细胞减灭术对晚期卵巢癌女性患者的生存有益，那么随着接受最大限度肿瘤细胞减灭术的女性比例增加，这类女性群体的中位生存时间将会延长。
确定了58项合适的研究，共纳入6962例晚期卵巢癌患者。采用多元线性回归分析以下变量对中位生存时间的影响：每个队列中接受最大限度肿瘤细胞减灭术的比例、含铂化疗的使用情况、化疗的剂量强度、每个队列中IV期疾病患者的比例以及研究发表年份。
最大限度肿瘤细胞减灭术仅使中位生存时间略有延长，但含铂化疗显著延长了中位生存时间。增加剂量强度也带来了有益的生存获益。
肿瘤细胞减灭术可能对晚期卵巢癌女性患者的生存影响较小。所用化疗类型更为重要。
